Literature DB >> 1202078

Metabolism of prostaglandins A1 and E1 in man.

M Golub, P Zia, M Matsuno, R Horton.   

Abstract

To investigate the in vivo whole blood metabolic clearance rates and sites of metabolism of prostaglandins A1 and E1 in man, constant infusions of the tritiated compounds were administered to normal subjects and to patients undergoing cardiac catheterization. The whole blood metabolic clearance rate of [3H]prostaglandin A1 in eight men was 5,003 +/- 864 liters/day (SD) or 2,546 +/- 513 liters/day per m2 (SD). Nonradioactive prostaglandin A1 was similarly infused in two subjects, and the metabolic clearance rates were determined, utilizing a specific radioimmunoassay. The clearance rates with this method correlated closely with those determined by the isotope infusions. Extraction studies of prostaglandin A1 showed that pulmonary, splanchnic, renal, and extremity perfusions resulted in 8.1 +/- 4.1, 56.1 +/- 10.1, 50.3 +/- 3.4, and 34.4 +/- 5.9% (SEM) removal, respectively. With [3H]=prostaglandin E1, the whole blood metabolic clearance rate was determined from the pulmonary artery concentration in three patients and averaged 4,832 +/- 1,518 liters/day (SD) or 2,686 +/- 654 liters/day per m2 (SD). Pulmonary extraction was 67.8 +/- 6.8% (SEM) and extremity removal averaged 6.6 +/- 4.9% (SEM). These results indicate that A prostaglandins are metabolized by several organs, such as the liver and kidney, and possibly by intravascular pathways as well. In man, the E prostaglandins are primarily metabolized by the lung, but extraction is not complete and approximately one-third may escape lung metabolism. Thus, these findings suggest that both E and A prostaglandins in the venous circulation may reach the systemic circulation in man.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1202078      PMCID: PMC333118          DOI: 10.1172/JCI108221

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  21 in total

1.  Differential in vivo pulmonary degradation of prostaglandins E1, B1, and A1.

Authors:  R P Robertson
Journal:  Am J Physiol       Date:  1975-01

Review 2.  Prostaglandins and the renal antihypertensive and natriuretic endocrine function.

Authors:  J B Lee
Journal:  Recent Prog Horm Res       Date:  1974

3.  Metabolism of prostaglandin A. I. The kidney cortex as a major site of PGA2 degradation.

Authors:  A A Attallah; W Payakkapan; J B Lee
Journal:  Life Sci       Date:  1974-04-16       Impact factor: 5.037

4.  In vivo conversion of dehydroisoandrosterone to plasma androstenedione and testosterone in man.

Authors:  R Horton; J F Tait
Journal:  J Clin Endocrinol Metab       Date:  1967-01       Impact factor: 5.958

5.  Effect of prostaglandin E1 on blood pressure and heart rate in the dog. Prostaglandin and related factors 48.

Authors:  L A Carlson; L Orö
Journal:  Acta Physiol Scand       Date:  1966-05

6.  On the metabolism of prostaglandins E 1 and E 2 in man.

Authors:  M Hamberg; B Samuelsson
Journal:  J Biol Chem       Date:  1971-11-25       Impact factor: 5.157

7.  Metabolism of prostaglandin E 2 in guinea pig liver.

Authors:  M Hamberg; U Israelsson; B Samuelsson
Journal:  Ann N Y Acad Sci       Date:  1971-04-30       Impact factor: 5.691

8.  The distribution of 15-hydroxy prostaglandin dehydrogenase and prostaglandin-delta 13-reductase in tissues of the swine.

Authors:  E Anggård; C Larsson; B Samuelsson
Journal:  Acta Physiol Scand       Date:  1971-03

9.  Prostaglandins: their disappearance from and release into the circulation.

Authors:  S H Ferreira; J R Vane
Journal:  Nature       Date:  1967-12-02       Impact factor: 49.962

10.  Dehydration of prostaglandins: study by spectroscopic method.

Authors:  N H Andersen
Journal:  J Lipid Res       Date:  1969-05       Impact factor: 5.922

View more
  31 in total

1.  Formation of biologically active 13,14-dihydro-prostaglandin E1 during intravenous infusion of prostaglandin E1 in newborns with ductus arteriosus-dependent congenital heart disease.

Authors:  A Leonhardt; H Schweer; D Wolf; H W Seyberth
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

Review 2.  The biochemical properties of the pulmonary circulation.

Authors:  J A Pang; D M Geddes
Journal:  Lung       Date:  1981       Impact factor: 2.584

3.  Serum calcium in pulmonary tuberculosis.

Authors:  S C Sharma
Journal:  Postgrad Med J       Date:  1981-11       Impact factor: 2.401

4.  The effects of intraportal prostaglandin E1 administration on hepatic warm ischemia and reperfusion injury in dogs.

Authors:  E Totsuka; M Sasaki; K Takahashi; Y Toyoki; K Seino; S Chiba; S Narumi; K Hakamada; T Morita; M Konn
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

5.  Hyperkinetic shock in viral and pneumococcal pneumonias.

Authors:  J Dussan; B Regnier; T Darragon; B Teisseire; J R Le Gall; F Lemaire
Journal:  Intensive Care Med       Date:  1979-05       Impact factor: 17.440

6.  Prostaglandin E1 infusions for vascular insufficiency in progressive systemic sclerosis.

Authors:  M F Martin; P M Dowd; E F Ring; E D Cooke; P A Dieppe; J D Kirby
Journal:  Ann Rheum Dis       Date:  1981-08       Impact factor: 19.103

7.  Inhibition by indomethacin of the renal response to an acute saline load in the dog.

Authors:  A Nizet
Journal:  Pflugers Arch       Date:  1979-01-31       Impact factor: 3.657

8.  Prolonging the in vivo residence time of prostaglandin E(1) with biodegradable nanoparticles.

Authors:  Tsutomu Ishihara; Miyuki Takahashi; Megumu Higaki; Mitsuko Takenaga; Tohru Mizushima; Yutaka Mizushima
Journal:  Pharm Res       Date:  2008-02-22       Impact factor: 4.200

9.  Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome. A prospective trial.

Authors:  J W Holcroft; M J Vassar; C J Weber
Journal:  Ann Surg       Date:  1986-04       Impact factor: 12.969

10.  Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles.

Authors:  Tsutomu Ishihara; Miho Takeda; Haruka Sakamoto; Ayumi Kimoto; Chisa Kobayashi; Naoko Takasaki; Kanae Yuki; Ken-ichiro Tanaka; Mitsuko Takenaga; Rie Igarashi; Taishi Maeda; Naoki Yamakawa; Yoshinari Okamoto; Masami Otsuka; Tatsuhiro Ishida; Hiroshi Kiwada; Yutaka Mizushima; Tohru Mizushima
Journal:  Pharm Res       Date:  2009-07-25       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.